Mechanistic Roles of Mucin-16 in Ovarian Cancer

Structural Characteristics of Mucin-16 and Its Ovarian Cancer-Related Expression

Mucin-16 (also known as CA125) is a highly glycosylated transmembrane protein with a molecular weight exceeding 2000 kDa, encoded by the MUC16 gene located at human chromosome 19p13.2. Structurally, MUC16 comprises three main functional domains: an N-terminal signal peptide sequence, approximately 60 tandem repeat SEA domains (each containing 156 amino acids), a transmembrane region, and a short cytoplasmic tail. Under physiological conditions, MUC16 primarily expresses on coelomic epithelium and fallopian tube mucosa, functioning to form protective barriers and regulate local immune microenvironments. In epithelial ovarian cancer, MUC16 exhibits characteristic alterations: significantly upregulated expression (overexpressed in ~85% of serous ovarian cancers), abnormal glycosylation patterns (increased expression of Tn and sialyl-Tn antigens), and enhanced shedding (serum CA125 levels elevated 10–100-fold). These tumor-specific changes establish MUC16 as a key target for ovarian cancer diagnosis and therapy. Notably, MUC16 expression correlates positively with FIGO staging (50% positivity in stage I vs. ~100% in stage IV) and predicts poor prognosis, with high-expression patients showing 30% vs. 60% 5-year survival rates, indicating its potential value as a prognostic marker.

Molecular Mechanisms of MUC16 in Ovarian Cancer Metastasis

MUC16 promotes peritoneal metastasis and chemoresistance in ovarian cancer through multiple pathways. During metastasis initiation, its extracellular domain binds mesothelin (MSLN) to mediate heterotypic adhesion between tumor cells and peritoneal mesothelium, involving precise recognition of specific glycosylated epitopes in MUC16 tandem repeats and the MSLN N-terminal domain (binding constant Kd≈10nM). For metastatic colonization, MUC16 remodels the microenvironment by activating EGFR/PI3K/AKT/mTOR pathways to enhance cell survival (apoptosis reduced by 40–60%), upregulating MMP-2/9 to augment matrix degradation (collagen degradation area increased 2–3-fold), and inducing IL-6/STAT3 signaling to create a pro-inflammatory milieu (IL-6 secretion elevated 5–8-fold). Soluble CA125, the shed form of MUC16, forms an immunosuppressive network by binding Galectin-1, inhibiting NK and CD8+ T cell cytotoxicity (reduced by 50–70%) and promoting Treg expansion (ratio increased 2–4-fold), providing molecular insights into ovarian cancer’s peritoneal dissemination.

Applications of CA125 in Ovarian Cancer Diagnosis and Monitoring

As the first FDA-approved ovarian cancer biomarker, CA125 testing offers multiple clinical values. Diagnostically, CA125 assays based on OC125 and M11 mAbs (cutoff 35U/mL) exhibit 80% sensitivity and 90% specificity for epithelial ovarian cancer, with improved accuracy (AUC 0.93) when combined with HE4 (ROMA index). For treatment monitoring, CA125 dynamics (per GCIG criteria) assess chemotherapy response: complete responders typically normalize CA125 (<35U/mL) within 3 cycles, while persistent elevation predicts primary resistance (85% accuracy). Recurrence surveillance shows CA125 elevation precedes imaging findings by 3–6 months (75% sensitivity, 95% specificity). Algorithms like the CPH model enable personalized recurrence risk assessment, with CA125 >20U/mL indicating 3–5-fold higher 6-month recurrence risk. Limitations include lower early-stage positivity (50% in stage I) and false positives in endometriosis/pelvic inflammation (15–20%), necessitating combined imaging and clinical evaluation.

Advances in MUC16-Targeted Therapies

Targeted therapies against MUC16 have seen significant breakthroughs. The antibody-drug conjugate DMUC4064A, linking anti-MUC16 antibody to MMAE, showed manageable safety (grade ≥3 toxicity <20%) and preliminary efficacy (ORR 25%, DCR 60%) in phase I trials. MUC16-specific CAR-T cells (e.g., 4H11 scFv with CD28 costimulation) significantly inhibited PDX model growth (tumor volume reduction 70–90%) and completed phase I dose escalation (NCT02498912). Bispecific antibodies (MUC16×CD3 bsAb) induced complete tumor regression in animal models with long-term immune memory (6-month relapse-free survival). MUC16-based vaccines (e.g., Ad-sig-hMUC-1/ecdCD40L) elicited specific T cell responses (IFN-γ+ T cells increased 5–10-fold) in phase I/II trials. Challenges include soluble CA125 neutralization (antibody half-life reduced 30–50%), antigen loss due to tumor heterogeneity (30% incidence after 6 months), and immunosuppressive microenvironment constraints (T cell infiltration reduced 50–70%).

Research Challenges and Future Directions

Key scientific questions in MUC16 research include elucidating regulatory networks of abnormal glycosylation (e.g., specific glycosyltransferases), resolving functional differences between splice variants (membrane-bound vs. soluble), and exploring associations with cancer stem cell properties (e.g., CD44+ subpopulation regulation). Clinical translation challenges involve enhancing early diagnostic sensitivity (e.g., nanobodies targeting MUC16 glycoforms), overcoming treatment resistance (e.g., combinations with PARP inhibitors/immune checkpoint blockers), and establishing reliable response predictors (e.g., MUC16 epitope maps/glycosylation signatures). Future directions should prioritize mass spectrometry imaging for MUC16 spatial heterogeneity, liquid biopsy methods targeting exosomal MUC16, and epigenetic regulators (e.g., DNMT inhibitors) for MUC16 expression modulation. With advances in glycoproteomics, single-cell sequencing, and microfluidics, MUC16 research is transitioning from single-marker analysis to systems biology, driving precision diagnostics and therapies for ovarian cancer.

Click on the product catalog numbers below to access detailed information on our official website.

Product Information